![]() |
市場調查報告書
商品編碼
1348458
輸血設備的全球市場:規模,佔有率,趨勢分析(2024年~2030年):MedCoreBlood Transfusion Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2023年,全球輸液治療市場規模達117億美元,較上年112億美元成長4.5%。據預測,這一數字還將繼續上升,複合年增長率 (CAGR) 為 3.7%,最終在預測期內達到 150 億美元。目前,全球輸液治療市場主要由產業巨頭碧迪公司(BD)和貝朗公司推動。
全球輸液治療市場目前正在經歷顯著成長,這主要是由於新興市場獲得醫療保健服務的機會迅速增加。這些地區的醫療基礎設施大大改善,交通便利,這刺激了輸液治療的需求。這些地區的人口增長以及疾病管理和醫療保健服務能力的提高進一步推動了這種不斷增長的需求。
加強的醫療保健基礎設施正在為更多的人提供輸液治療服務,從而改善患者的治療效果並擴大治療選擇。新興市場的這種動態擴張為行業參與者提供了巨大的機會,可以滿足對輸液治療解決方案快速增長的需求。
2023年,碧迪公司(BD)鞏固了其在全球輸液治療市場的主導地位,在除輸液過濾器以外的所有細分市場中均佔第一。BD 的非凡成功歸功於其強大的全球品牌影響力和廣泛的輸液治療產品,這兩者都對整體銷售成長做出了重大貢獻。
貝朗在全球輸液治療市場排名第二。與 BD 一樣,貝朗擁有全面的產品組合,涵蓋除輸液過濾器領域之外的幾乎所有細分市場。然而,貝朗值得注意的是,與BD相比,固定設備輸液幫浦的選擇範圍稍窄。
本報告提供全球輸血設備市場相關調查,提供市場概要,以及各市場區隔,各地區趨勢,競爭情形等資訊。
In 2023, the global blood transfusion set market reported a total value of $480.1 million, reflecting a 3.5% decline from the $464.1 million recorded in 2022. However, projections for the upcoming period indicate a positive growth trajectory, with a compound annual growth rate (CAGR) of 3.0%, ultimately reaching $591 million. Currently, the global blood transfusion set market is under the dominion of Becton Dickinson (BD), Baxter, and ICU Medical.
Our comprehensive medical market research encompassed a thorough analysis of more than 15 blood transfusion companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
The prevalence of chronic illnesses like cancer, cardiovascular diseases, and blood disorders is on the rise, leading to an increased need for regular blood transfusions as a crucial aspect of treatment. With the growing incidence of these conditions, the demand for blood transfusion kits becomes even more pronounced, serving as a lifeline for individuals grappling with these significant health challenges. The increasing prevalence of chronic diseases underscores the essential role played by blood transfusion kits in providing essential care and support to those in need, ultimately contributing to improved healthcare outcomes.
Becton Dickinson (BD) secured its top position among competitors in the blood transfusion device market. BD offered a comprehensive range of blood IV sets, available in both pump-based and gravity-based configurations. These sets featured essential components such as a 180-µm filter, a pressure pump, a needleless connector, and male Luer lock adapters. They were specifically designed for use with BD's Alaris brand of infusion pumps. BD's presence in the IV set market was substantial, and in 2015, the company bolstered its industry standing by acquiring infusion therapy products from CareFusion.
Baxter held the second spot in the blood transfusion device market. The company provided a diverse array of blood collection and administration sets, including standard blood in-line filters, Y-sites, male Luer lock injection adapters, and a pressure pump. Baxter's robust position in both the IV set and infusion pump markets allowed them to drive sales of blood sets effectively. Their product lineup encompassed dual-chamber and single-chamber devices.
ICU Medical, ranking third among competitors in the blood transfusion device market, demonstrated particular strength in North America. The company boasted an extensive range of products and disposables within its infusion therapy portfolio, which was further expanded through the acquisition of Smiths Medical. ICU Medical offered transfusion sets compatible with both gravity and infusion pumps. Additionally, they provided three distinct blood collection and administration tubing options, along with associated accessories, as part of their Saf-T Wing™ product line.
Blood Transfusion Market